Treatment	Talc slurry	Talc poudrage	Bleomycin	Tetracycline	C.parvum	Placebo	Mepacrine
Talc poudrage	0.60 (0.15, 2.37); Tau2 = 0.54; I 2= 31%; n = 2	NA	‐	‐	‐	‐	‐
Bleomycin	0.90 (0.31, 2.56); Tau2 = 0.10; I2 = 11%; n = 3*	0.87 (0.11, 7.05); n = 1	NA	‐	‐	‐	‐
Tetracycline	0.92 (0.23, 3.63); n = 1*	‐	0.49 (0.16, 1.50); Tau2 = 0.63; I2 = 39%; n = 5	NA	‐	‐	‐
C. parvum	NA	NA	2.30 (0.90, 5.92); Tau2 = 0; n = 2; I2 = 0%	288.00 (16.62, 4991); n = 1	NA	‐	‐
Interferon	NA	NA	0.01, (0.00, 0.11); n = 1	NA	NA	NA	NA
Iodine	0.63 (0.09, 4.28); n = 1	0.24 (0.02, 2.33); n = 1	NA	NA	NA	NA	NA
Placebo	NA	NA	NA	NA	NA	NA	‐
Mustine	NA	NA	NA	NA	0.23 (0.01, 6.25) n = 1	NA	NA
Mitoxantrone	NA	NA	0.90 (0.30, 2.71); n = 1	NA	NA	3.28 (1.26, 8.49); n = 1	NA
Mepacrine	NA	NA	1.91 (0.52, 7.01); n = 1	8.00 (1.13, 56.79); n = 1	NA	62.43 (2.85, 1365.5); n = 1*	NA
Doxycycline	NA	NA	0.37 (0.01, 12.35); Tau2 = 5.18; I2 = 80%; n = 2	NA	0.14 (0.03, 0.54); n = 1	NA	NA
Triethylenethiophosphoramide	NA	NA	NA	NA	NA	3.52 (0.15, 81.92); n = 1*	0.04 (0.01, 0.30); n =1*
n = the number of studies included in the pair‐wise comparison. * indicates that the comparison included a three‐arm study. NA = no direct pair‐wise comparison available. Results that are statistically significant at the conventional level of P < 0.05 are shaded in grey‐ indicates the odds ratio is already expressed elsewhere in the table comparing the interventions the other way around.